AbbVie recently announced positive top-line results from its Phase 3 Select-Next trial, which evaluated upadacitinib as a treatment for rheumatoid arthritis patients.
The drug was developed specifically for those patients with moderate to severe RA who did not respond well to conventional synthetic DMARD (csDMARD) treatment.
The results of the study indicate that, after 12 weeks of treatment, upadacitinib met the primary endpoints – ACR20 and low disease activity. The drug also met key secondary endpoints, including ACR50 ACR70 and clinical remission.
"We are excited by these promising results for upadacitinib. Selective inhibition of the JAK1 pathway may offer a novel treatment for rheumatoid arthritis patients who do not adequately respond to conventional therapies," Dr. Michael Severino, executive vice president of research and development and chief scientific officer at AbbVie, said in a statement. "We are especially encouraged by the results on the more stringent measures of efficacy, such as ACR70, low disease activity and clinical remission. We look forward to seeing the full results from our Phase 3 program. AbbVie's longstanding leadership in the treatment of immune-mediated diseases provides an opportunity to build upon our understanding and develop innovative therapies to address unmet patient needs."
Alerts Sign-up